According to Cellectis's latest financial reports the company's current revenue (TTM) is $16.38 M. In 2022 the company made a revenue of $19.05 M a decrease over the years 2021 revenue that were of $57.29 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $16.38 M | -14.04% |
2022 | $19.05 M | -66.74% |
2021 | $57.29 M | -21.65% |
2020 | $73.12 M | 383.92% |
2019 | $15.11 M | 17.47% |
2018 | $12.86 M | -48.8% |
2017 | $25.12 M | -40.82% |
2016 | $42.45 M | -22.32% |
2015 | $54.65 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Regeneron Pharmaceuticals REGN | $13.11 B | 79,970.81% | ๐บ๐ธ USA |
uniQure QURE | $15.84 M | -3.29% | ๐ณ๐ฑ Netherlands |
Novavax NVAX | $0.69 B | 4,133.07% | ๐บ๐ธ USA |
Flexion Therapeutics
FLXN | $0.10 B | 512.87% | ๐บ๐ธ USA |